While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

At the helm of Denmark’s economic success is Novo Nordisk, the pharma company that makes Ozempic and Wegovy, blockbuster ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Hims & Hers Health ( HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...